Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX)

Market Closed
8 Dec, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
8. 27
+0.47
+6.03%
After Hours
$
8. 26
-0.01 -0.12%
294.72M Market Cap
- P/E Ratio
0% Div Yield
467,227 Volume
- Eps
$ 7.8
Previous Close
Day Range
7.79 8.29
Year Range
1.78 8.45
Want to track KYTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) - February 7, 2025 Deadline to Join - Contact Levi & Korsinsky

Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) - February 7, 2025 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX

Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX

Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX

February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX

Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ:KYTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Accesswire | 11 months ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Shareholders

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Shareholders

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Kyverna Therapeutics Inc

The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Kyverna Therapeutics Inc

LOS ANGELES, CA / ACCESSWIRE / December 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to contact the firm before February 7, 2025.

Accesswire | 11 months ago
Lost Money on Kyverna Therapeutics, Inc. (KYTX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Lost Money on Kyverna Therapeutics, Inc. (KYTX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESSWIRE / December 31, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kyverna securities pursuant to the registration statement and prospectus issued in connection with the Company's February 8, 2024 initial public offering ("IPO").

Accesswire | 11 months ago
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - KYTX

Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - KYTX

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
Shareholders that lost money on Kyverna Therapeutics, Inc. (KYTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Shareholders that lost money on Kyverna Therapeutics, Inc. (KYTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 11 months ago
Loading...
Load More